Key Highlights
- Shares of Soleno Therapeutics (SLNO) jumped more than 30% during premarket hours Monday following acquisition reports
- Neurocrine Biosciences (NBIX) is reportedly close to finalizing a deal to purchase Soleno worth $2.5B or higher
- The acquisition could price SLNO shares between the low and mid-$50s range
- According to the Financial Times, an agreement may be reached as early as Monday, April 6
- Shares of Neurocrine declined 0.4% premarket following the announcement
Soleno Therapeutics has experienced a challenging start to 2026 — posting roughly 14% losses year to date — but Monday morning brought a dramatic reversal.
Soleno Therapeutics, Inc., SLNO
According to a Financial Times report, Neurocrine Biosciences has entered late-stage negotiations to acquire the rare disease-focused biotech company in a transaction exceeding $2.5 billion. News of the potential deal pushed SLNO shares up more than 30% before regular market hours.
Neurocrine nears $2.5bn-plus deal for biotech behind obesity disorder treatment https://t.co/t7RIhvgwIb
— Financial Times (@FT) April 6, 2026
The proposed transaction would place Soleno’s valuation between the low and mid-$50s per share. Negotiations are reportedly progressing rapidly, with the FT indicating that both parties could reach an agreement as soon as Monday.
Soleno’s primary commercial product is Vykat XR, which debuted last year as a treatment for hyperphagia — a condition associated with Prader-Willi syndrome. This condition triggers uncontrollable, chronic hunger that can result in severe health complications such as gastric rupture, choking incidents, obesity, and heart disease.
Prader-Willi syndrome represents a rare genetic condition, affecting approximately one in 15,000 live births globally. Vykat XR holds the distinction of being the first commercially available medication specifically approved to address hunger-related symptoms associated with this syndrome.
Industry analysts have projected Vykat XR could achieve peak yearly sales reaching $2.3 billion — a figure that has evidently attracted significant interest from Neurocrine.
Neurocrine Expands Into Rare Disease Territory
Neurocrine presently maintains a market capitalization of approximately $13.21 billion. The company’s existing product lineup features Ingrezza, designed to manage involuntary movements associated with Huntington’s disease, alongside multiple other marketed therapies and developmental pipeline assets.
Acquiring Vykat XR would establish Neurocrine’s presence in the rare disease and orphan drug market segment, where companies typically benefit from robust pricing capabilities and reduced competitive pressures.
Neurocrine’s shares fell 0.4% in premarket activity Monday. This modest decline represents a common market response when acquiring companies announce major purchases — reflecting investor concerns about acquisition premiums.
Understanding SLNO’s Recent Performance
Despite Monday’s sharp increase, SLNO had posted approximately 14% losses in 2026 prior to this week. The stock faced headwinds even as analysts maintained optimistic projections regarding Vykat XR’s market opportunity.
According to TipRanks, SLNO currently carries a Strong Buy rating based on consensus from 11 analysts. The mean price target stands at $101.09, while the highest projection reaches $125.
At the reported transaction price between the low and mid-$50s per share, the acquisition would settle considerably below analyst price targets — although it would still deliver a significant premium compared to SLNO’s recent trading levels.
The Financial Times report referenced individuals with direct knowledge of the negotiations, emphasizing that discussions are advancing smoothly and accelerating toward a potential final agreement.
